Anus basaloid carcinoma

Summary

Anus basaloid carcinoma (MONDO:0004130) is a cancer and 4 clinical trials. Top therapeutic interventions include nivolumab and fludeoxyglucose f 18. A subtype of basaloid squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anus basaloid carcinoma
Mondo ID	MONDO:0004130
DOID	DOID:7174
NCIT	C8256
UMLS	C0280470
MedGen	79125
GARD	0023839
Anatomy (UBERON)	UBERON:0001245
Is cancer (heuristic)	yes

Also known as: anal basaloid carcinoma · anus basaloid squamous cell carcinoma · basaloid carcinoma of anus · basaloid carcinoma of the anus

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › basaloid squamous cell carcinoma › anus basaloid carcinoma

Related subtypes (6): cervical basaloid carcinoma, basaloid carcinoma of the penis, vulvar basaloid squamous cell carcinoma, skin basaloid carcinoma, thymic basaloid carcinoma, esophageal basaloid carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03233711	PHASE3	ACTIVE_NOT_RECRUITING	Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT04444921	PHASE3	ACTIVE_NOT_RECRUITING	EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT04166318	PHASE2	ACTIVE_NOT_RECRUITING	Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT02560298	PHASE2	UNKNOWN	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NIVOLUMAB	4	2
FLUDEOXYGLUCOSE F 18	4	1